With years of experience in drug discovery, Creative Biolabs has successfully launched an innovative anti-fungal drug platform with multiple high-end technologies. We offer a full range of anti-fungal drug discovery services for our clients. Here is an introduction about isoleucyl-tRNA synthase which can be used as potential targets for antifungal drug discovery.
Why Need to Discover New Anti-Fungal Drugs?
Over the past 30 years, the importance of antifungal drugs in the practice of modern medicine has increased dramatically. Because the vast majority of life-threatening fungal infections affect people with altered immune function, the increased incidence of invasive fungal infections can be correlated with an expansion in the number of people living with conditions or treatments that affect immune function. Currently, two of the three classes of antifungal drugs (azoles and polyenes) had already been introduced into the clinics by 1980 and the third class (echinocandins) had been discovered. However, even with these newest therapies, the clinical outcomes for most invasive fungal infections are far from ideal.
Isoleucyl-tRNA Synthase as Anti-Fungal Drug Target
Isoleucyl-tRNA synthetase (IleRS) is an aminoacyl-tRNA synthetase whose essential function is to aminoacylate tRNAIle with isoleucine. Like some other aminoacyl-tRNA synthetases, IleRS can mischarge tRNAIle and correct this misacylation through a separate post-transfer editing function. Several articles have reported that IleRS is an effective antifungal target.
Fig.1 Signaling network mediated by mammalian AARSs. (Park, 2008)
One biological pathway that has been thoroughly validated as a target for anti-infective compounds in a wide range of microbes is the process of protein translation. Most antibiotics that target protein translation interact with microbial ribosomes themselves binding directly to the rRNA or ribosomal subunit proteins. However, additional molecules within the broader process of protein translation can act as targets for drugs. One such target for existing and future antimicrobial therapeutics is the aminoacyl-tRNA synthetase (aaRS) family. This family of enzymes catalyzes the attachment of amino acids to their cognate tRNAs to produce the aminoacyl tRNAs (also aa-tRNA or charged tRNA) that are the substrates for translation. The aaRSs enzymes are not only responsible for producing the raw materials for translation, but also for ensuring the fidelity of translation from nucleic acid to amino acid information. Disruption of aaRSs therefore interrupts or poisons the process of protein translation.
With the help of our well-established technologies and experienced scientists, Creative Biolabs offers antifungal drug discovery services to promote your drug discovery development. We provide very flexible options for each specific case. We are happy to make it accessible to all kinds of research and industrial customers. Besides, we are open to discussions. Please contact us for more information.
Reference
For Research Use Only.
